Hsa_circ_0004194 suppresses colorectal cancer progression via hsa-miR-27a-3p

Heliyon. 2024 Oct 20;10(20):e39549. doi: 10.1016/j.heliyon.2024.e39549. eCollection 2024 Oct 30.

Abstract

Aims: To investigate the functional role and the underlying molecular mechanisms associated with hsa_circ_0004194 in the context of colorectal cancer (CRC) and to elucidate its impact on cancer progression.

Results: A notable and statistically significant decrease in the expression levels of hsa_circ_0004194 was observed specifically within CRC tissues when compared to non-tumor colorectal mucosa tissues. Functional evaluations, such as CCK8 assays, plate clone formation analysis, and transwell migration assays, our study revealed hsa_circ_0004194 significantly reduced the activity behavior of CRC cells. This overexpression of hsa_circ_0004194 effectively hindered these key cellular processes, demonstrating its role in suppressing the aggressive behaviors of CRC cells. Additionally, in vivo experiments utilizing mouse xenograft models exhibited that the upregulation of hsa_circ_0004194 significantly attenuated tumor growth, reduced tumor volume, and diminished liver metastasis. Further mechanistic investigation, through the utilization of RNA pull-down and luciferase reporter assays, uncovered that hsa_circ_0004194 sequestered hsa-miR-27a-3p, thereby enhancing retinoic acid X receptor α (RXRα)' expression which is in CRC cells. Moreover, this circular RNA also impeded the signaling pathway of Wnt/β-catenin.

Conclusion: Our study is the first to demonstrate that hsa_circ_0004194 exhibits downregulated expression in CRC and functions as a ceRNA by binding to and sequestering hsa-miR-27a-3p, thereby modulating the RXRα/β-catenin signaling pathway to inhibit CRC progression. This discovery suggests that hsa_circ_0004194 holds significant potential as a therapeutic biomarker for patients with CRC.

Keywords: Colorectal cancer; Hsa-miR-27a-3p; RXRα; hsa_circ_0004194.